Sign up to get each new magazine issue delivered to your inbox

June 2022

While sizing up the pharmaceutical industry’s environmental impact often, and rightfully so, the focus is on industrial effluents from manufacturing facilities. But the improper disposal of drugs and antibiotics has long been known to be a major cause of harm to wildlife and the environment, and antimicrobial resistance. 


The June issue will also delve into the world of CAR-T treatments, and more specifically examine the ‘East-West’ divide in Europe when it comes to access to these innovative therapies. Particular challenges of cost and manufacturing expertise exist in delivering CAR-T therapy to some European Union states, and while access is relatively slower the demand for such approaches is only increasing.


All this plus the latest trends and innovations in the pharma industry, as well as up-to-date analysis and insight from GlobalData experts.


EDITORIAL

Editor | Manasi Vaidya

Writers | William Newton, Darcy Jimenez, Reynald Castaneda, Urte Fultinaviciute, Milena Izmirlieva.
Magazine Designer | Maria Gimenez

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Martina Labaiova, Will Ingham
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Tom McCormick

+44 207 8669440

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Tackling insulin prices Go to article: In this issueGo to article: CSafe GlobalGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: CommentGo to article: Why did the cannabis industry blossom during the pandemic?Go to article: Negative AdCom vote for Amylyx’s ALS drug AMX0035, but hope remainsGo to article: Will Russia’s invasion affect biopharmaceutical licensing agreements?Go to article: Fall from grace? What 2022 may have in stock for biopharmaceutical SPACsGo to article: BEA TechnologiesGo to article: In DepthGo to article: Insulin pricing: could an e-commerce approach cut costs?Go to article: Bacteria and balance: how understanding the vaginal microbiome can help discover new drugs Go to article: Big pharma’s gradual retreat on clinical trials in Russia Go to article: Covid-19, flu combo vaccines an advance but with rollout quandariesGo to article: FDA shows unease about marketing approval applications based on single-country tGo to article: In DataGo to article: How big is the gender pay gap in the pharma industry in Britain?Go to article: Where is trade most likely to be disrupted in pharma from the Russian invasion oGo to article: Big data innovation among pharma companies dropped off in the last quarterGo to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue